Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
Public ClinicalTrials.gov record NCT01022996. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will assess RAD001 in patients with refractory or relapsed Hodgkin Lymphoma that has progressed after high-dose chemotherapy and Autologous Stem cell transplant and/or after gemcitabine- or vinorelbine- or vinblastine-based treatment.
Study identification
- NCT ID
- NCT01022996
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 57 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2009 (Type not available)
- Primary completion
- Nov 2014 (Actual)
- Completion
- Nov 2014 (Actual)
- Last update posted
- May 18, 2016
2009 – 2014
United States locations
- U.S. sites
- 16
- U.S. states
- 15
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California at Los Angeles UCLS School of Medicine | Los Angeles | California | 90095 | — |
| Rocky Mountain Cancer Centers RMCC - Aurora | Greenwood Village | Colorado | — | — |
| MD Anderson Cancer Center - Orlando | Orlando | Florida | 32806 | — |
| Emory University School of Medicine/Winship Cancer Institute Emory University Med School | Atlanta | Georgia | 30322 | — |
| Lurie Children's Hospital of Chicago Robert H. Lurie Comp Cancer | Chicago | Illinois | 60611 | — |
| Indiana University Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Karmanos Cancer Institute Karmanos-1 | Detroit | Michigan | 48201 | — |
| Mayo Clinic - Rochester Mayo Lymphoma Group | Rochester | Minnesota | 55905 | — |
| Washington University School Of Medicine-Siteman Cancer Ctr StudyCoordinator:CLBH589B2201 | St Louis | Missouri | 63110 | — |
| New York Presbyterian Hospital Weill Cornell Med Ctr | New York | New York | 10021 | — |
| Duke University Medical Center Duke University Medical Ctr | Durham | North Carolina | 27710 | — |
| University of Tennessee Cancer Institute Univ Tennessee Cancer | Memphis | Tennessee | 38104 | — |
| University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(3) | Houston | Texas | 77030-4009 | — |
| University of Wisconsin Comprehensive Cancer Center Clinical Science Center - H4 | Madison | Wisconsin | 53792 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01022996, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 18, 2016 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01022996 live on ClinicalTrials.gov.